Total Payments
$241,033
2024 Payments
$45,397
Companies
41
Transactions
624
Medicare Patients
4,608
Medicare Billing
$1.5M
Payment Breakdown by Category
Other$205,309 (85.2%)
Travel$23,452 (9.7%)
Food & Beverage$12,120 (5.0%)
Education$152.55 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $167,684 | 93 | 69.6% |
| Honoraria | $37,625 | 32 | 15.6% |
| Travel and Lodging | $23,452 | 78 | 9.7% |
| Food and Beverage | $12,120 | 416 | 5.0% |
| Education | $152.55 | 5 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Fresenius USA Marketing, Inc. | $128,214 | 208 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $50,026 | 74 | $0 (2024) |
| Amgen Inc. | $17,847 | 67 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15,278 | 18 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $13,626 | 94 | $0 (2024) |
| Lilly USA, LLC | $12,682 | 17 | $0 (2024) |
| Horizon Therapeutics plc | $311.91 | 14 | $0 (2023) |
| OPKO Pharmaceuticals, LLC | $299.50 | 13 | $0 (2023) |
| Daiichi Sankyo Inc. | $297.95 | 19 | $0 (2022) |
| Mallinckrodt Hospital Products Inc. | $233.57 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $45,397 | 102 | Boehringer Ingelheim Pharmaceuticals, Inc. ($15,251) |
| 2023 | $34,457 | 80 | Bayer Healthcare Pharmaceuticals Inc. ($29,175) |
| 2022 | $20,634 | 77 | Bayer HealthCare Pharmaceuticals Inc. ($11,890) |
| 2021 | $13,999 | 66 | Fresenius USA Marketing, Inc. ($7,156) |
| 2020 | $11,137 | 60 | Fresenius USA Marketing, Inc. ($5,712) |
| 2019 | $30,022 | 67 | Fresenius USA Marketing, Inc. ($16,506) |
| 2018 | $18,741 | 60 | Fresenius USA Marketing, Inc. ($18,203) |
| 2017 | $66,645 | 112 | Fresenius USA Marketing, Inc. ($66,224) |
All Payment Transactions
624 individual payment records from CMS Open Payments — Page 1 of 25
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $22.21 | General |
| Category: Inflammation | ||||||
| 12/16/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: CRITICAL CARE | ||||||
| 12/03/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Honoraria | Cash or cash equivalent | $1,000.00 | General |
| Category: Phosphate binder for ESRD | ||||||
| 11/28/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $584.51 | General |
| Category: Cardio-renal | ||||||
| 11/28/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $9.00 | General |
| Category: Cardio-renal | ||||||
| 11/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,888.00 | General |
| Category: Cardio-renal | ||||||
| 11/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $201.25 | General |
| Category: Cardio-renal | ||||||
| 11/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $122.79 | General |
| Category: Cardio-renal | ||||||
| 11/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,650.00 | General |
| Category: DIABETES | ||||||
| 11/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $60.30 | General |
| Category: DIABETES | ||||||
| 11/07/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.49 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/28/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $960.00 | General |
| Category: DIABETES | ||||||
| 10/28/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $30.80 | General |
| Category: CRITICAL CARE | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $22.67 | General |
| 10/21/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $13.81 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $106.86 | General |
| Category: DIABETES | ||||||
| 10/08/2024 | Amgen Inc. | Aranesp (Biological), Parsabiv, TAVNEOS | Food and Beverage | In-kind items and services | $15.62 | General |
| Category: Nephrology | ||||||
| 10/07/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Honoraria | Cash or cash equivalent | $2,000.00 | General |
| Category: Phosphate binder for ESRD | ||||||
| 10/07/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Travel and Lodging | Cash or cash equivalent | $26.80 | General |
| Category: Phosphate binder for ESRD | ||||||
| 10/01/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | Cash or cash equivalent | $41.57 | General |
| Category: Phosphate binder for ESRD | ||||||
| 09/26/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $22.83 | General |
| Category: Diabetes | ||||||
| 09/23/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $18.92 | General |
| 09/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $960.00 | General |
| Category: DIABETES | ||||||
| 09/18/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: Diabetes | ||||||
| 09/17/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: CRITICAL CARE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 1,110 | 2,918 | $1.1M | $334,249 |
| 2022 | 13 | 1,102 | 3,195 | $1.3M | $359,775 |
| 2021 | 14 | 1,140 | 3,297 | $1.3M | $396,446 |
| 2020 | 14 | 1,256 | 5,105 | $1.2M | $441,399 |
Total Patients
4,608
Total Services
14,515
Medicare Billing
$1.5M
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 328 | 1,384 | $357,363 | $126,930 | 35.5% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 37 | 257 | $232,932 | $72,175 | 31.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 52 | 264 | $186,769 | $43,768 | 23.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 157 | 194 | $97,140 | $26,007 | 26.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 144 | 212 | $69,536 | $15,739 | 22.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 154 | 239 | $55,250 | $12,407 | 22.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 78 | 173 | $31,088 | $10,590 | 34.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 100 | 113 | $38,444 | $10,574 | 27.5% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 22 | 37 | $27,757 | $8,846 | 31.9% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 14 | 21 | $14,783 | $4,560 | 30.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 24 | 24 | $10,196 | $2,655 | 26.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 332 | 1,608 | $415,202 | $127,423 | 30.7% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 42 | 320 | $290,032 | $91,074 | 31.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 76 | 337 | $238,414 | $56,655 | 23.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 229 | 327 | $111,249 | $33,367 | 30.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 151 | 230 | $75,440 | $16,108 | 21.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 112 | 149 | $34,444 | $8,105 | 23.5% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2022 | 19 | 33 | $23,231 | $6,864 | 29.5% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 16 | 21 | $15,754 | $4,794 | 30.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 28 | 31 | $15,522 | $4,791 | 30.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 40 | 77 | $13,837 | $4,272 | 30.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 24 | 24 | $10,196 | $2,605 | 25.5% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 13 | 16 | $8,319 | $2,448 | 29.4% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 20 | 22 | $4,030 | $1,269 | 31.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 345 | 1,490 | $378,712 | $120,071 | 31.7% |
About Dr. Sandeep Shori, DO
Dr. Sandeep Shori, DO is a Nephrology healthcare provider based in Fort Worth, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790727329.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sandeep Shori, DO has received a total of $241,033 in payments from pharmaceutical and medical device companies, with $45,397 received in 2024. These payments were reported across 624 transactions from 41 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($167,684).
As a Medicare-enrolled provider, Shori has provided services to 4,608 Medicare beneficiaries, totaling 14,515 services with total Medicare billing of $1.5M. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Fort Worth, TX
- Active Since 06/11/2006
- Last Updated 03/23/2021
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1790727329
Products in Payments
- Velphoro (Drug) $124,716
- Kerendia (Drug) $47,350
- JARDIANCE (Drug) $27,960
- Parsabiv (Biological) $13,343
- LOKELMA (Drug) $13,087
- Parsabiv (Drug) $3,968
- Critline - Monitors (Device) $3,364
- FARXIGA (Drug) $539.55
- KRYSTEXXA (Biological) $364.87
- Veltassa (Drug) $306.01
- INJECTAFER (Drug) $297.95
- TAVNEOS (Drug) $285.22
- ACTHAR (Biological) $270.00
- Rayaldee (Drug) $221.18
- CoreValve Evolut (Device) $152.29
- AQUADEX SMARTFLOW CONSOLE (Device) $149.81
- Renal - Acute (Device) $147.93
- BENLYSTA (Biological) $128.63
- JYNARQUE (Drug) $122.07
- Tavneos (Drug) $109.36
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Fort Worth
Michael Aragon, M.d, M.D
Nephrology — Payments: $138,471
Nephrology $138,471
Dr. Bernard Fischbach, M.d, M.D
Nephrology — Payments: $124,485
Nephrology $124,485
Renee Ellis, M.d, M.D
Nephrology — Payments: $46,269
Nephrology $46,269
Dr. Oladapo Afolabi, Md, MD
Nephrology — Payments: $18,976
Nephrology $18,976
Dr. Daniel Richey, D.o, D.O
Nephrology — Payments: $8,530
Nephrology $8,530
Dr. Raju Patil, M.d., M.p.h, M.D., M.P.H
Nephrology — Payments: $6,779
Nephrology $6,779